China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National Medical Product Administration (NMPA) for two of its drug candidates, SHR-1654 and SHR-2001. These molecules are set for assessment as potential treatments for rheumatoid arthritis and systemic lupus erythematosus, respectively.
SHR-1654: A Novel Treatment for Rheumatoid Arthritis
SHR-1654, an in-house developed product, is designed for subcutaneous administration and targets a unique mechanism not currently addressed by any commercially available drugs globally. This underscores the potential innovation and significance of SHR-1654 in the treatment landscape for rheumatoid arthritis.
SHR-2001: A Pioneering Therapy for Systemic Lupus Erythematosus
Similarly, SHR-2001 is an antibody cytokine fusion protein independently developed by Jiangsu Hengrui, also administered subcutaneously in clinical practice. Like SHR-1654, SHR-2001 has no similar commercially available counterparts globally, indicating its potential to offer a new treatment option for patients with systemic lupus erythematosus.-Fineline Info & Tech
